BPC-157 in 2026: not banned, not approved, not compoundable
Three separate questions get asked as one. BPC-157 is not a controlled substance, is not an FDA-approved drug, and has no lawful 503A compounding pathway. What the molecule is and where each answer comes from, dated.
BPC-157 is not banned in the United States, is not an FDA-approved drug, and cannot lawfully be compounded under section 503A, all as of September 21, 2026. Those are three different questions with three different sources, and the "legal now" stories of spring and summer 2026 come from running them together. Each answer below is dated to the FDA, WADA or PubChem document it comes from.
What BPC-157 is
BPC-157 is a synthetic pentadecapeptide: fifteen amino-acid residues, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written in one-letter code as GEPPPGKPADDAGLV. PubChem (CID 9941957) gives the formula C62H98N16O22, an average molecular weight of 1419.5 and a monoisotopic mass of 1418.704, with CAS 137525-51-0 and the synonyms Bepecin, PL-14736 and PLD-116. PubChem describes it as a fifteen-residue fragment of a gastric peptide abbreviated BPC, for body protection compound, and lists "Gastric Juice Peptide Fragment" among its names. It carries no terminal modifications and no non-standard residues, and in the literature it is handled as the free base or the acetate salt. FDA's July 2026 advisory materials evaluated both forms separately.
Its human research record is thin. ClinicalTrials.gov held four BPC-157 records on September 21, 2026: a Phase 1 study in Mexico with an unknown status, a Phase 1 study at the University of Arkansas listed as not yet recruiting, a Phase 2 study by Hudson Biotech in China, and a completed dietary-gummy study by a wellness company. No sponsor is running a US pivotal program. We stock BPC-157 as a lyophilized research vial with a named manufacturer and a second independent assay, and that is all this article will say about our product.
Is BPC-157 banned?
No. There is no federal ban on BPC-157. It is not a controlled substance; the Controlled Substances Act's anabolic-steroid definition is built around substances "chemically and pharmacologically related to testosterone," and a fifteen-residue peptide is not one. FDA has never issued a rule prohibiting it. What FDA has done is regard it as an unapproved new drug when it is sold with claims, which is a statement about the seller's intent rather than a prohibition on the molecule.
The word "banned" does apply in one arena, and it is sport, not law. WADA's 2026 Prohibited List names BPC-157 as an example under section S0, the class for substances "with no current approval by any governmental regulatory health authority for human therapeutic use," prohibited at all times. S0 is the class for substances with no approval anywhere, so WADA's placement is itself a statement of BPC-157's regulatory status, and BPC-157 has been an S0 example since the 2022 List; the 2026 release notes no change. It is not in S2 with the growth hormone releasing factors and growth factors. The S0 text, and how the WADA sections map onto research peptides, is set out in WADA S0, S2 and where research peptides sit on the Prohibited List.
Is BPC-157 FDA-approved?
No. There is no BPC-157 product in Drugs@FDA, and the paperwork trail says so from several directions. The 503A bulks list, to which BPC-157 was nominated, is reserved by statute for substances that have no USP or NF monograph and are not "components of drugs approved by the Secretary." A nomination to that list is an acknowledgment that no approved product exists. WADA's S0 wording, quoted above, says the same thing in different words.
FDA's own description of the substance, written when it placed BPC-157 in Category 2 on September 29, 2023, is still on the agency's page:
Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.FDA, Category 2 page, content current as of April 22, 2026
Approval would require a sponsor to file an application under section 505 with the evidence that FDA says it does not have. As of September 21, 2026 no such application is public, and the only US drug trial on the register has not begun recruiting.
Can BPC-157 be compounded?
Not under section 503A, as of September 21, 2026. The statute allows a state-licensed pharmacy or a physician to compound from a bulk substance only if that substance (1) has a USP or NF monograph, (2) is a component of an FDA-approved drug, or (3) is on the 503A bulks list. BPC-157 has no monograph, is a component of no approved drug, and is not on the list, which in the 2024 edition of 21 CFR 216.23 holds six substances and no peptides.
What changed in 2026 was FDA's interim sorting, and the change was made by the nominators, not by FDA. From September 29, 2023 BPC-157 sat in 503A Category 2, the group FDA says "may present significant safety risks." On FDA's page dated April 22, 2026 it appears under "Bulk drug substances nominated but withdrawn," with the sentence that the substances "were withdrawn by the nominators." After withdrawal BPC-157 is in no category. It is not in Category 1, where FDA's stated policy is that it "does not intend to take action against a compounder" while evaluation continues; the Category 1 document updated May 14, 2026 does not contain it. So the enforcement discretion that people mean when they say "legal to compound" does not reach BPC-157.
On July 23, 2026 FDA put BPC-157 free base and BPC-157 acetate to the Pharmacy Compounding Advisory Committee, having stated its own position in the briefing document: "FDA is proposing that BPC-157 (free base) NOT be included on the 503A Bulks List." Press reports (TIME and OpenLoop Health) give the committee's vote as 8 yes, 6 no and 1 abstention. FDA has published no vote record, and the committee's recommendations are, in FDA's words, "non-binding." Adding a substance to the list requires rulemaking. As of September 21, 2026 no proposed rule, notice or press release on BPC-157 has appeared on fda.gov or federalregister.gov. The three 2026 events and their tracker are in Category 1, Category 2 and the 503A bulks list.
On the 503B side, BPC-157 does not appear in any category of FDA's 503B list dated March 21, 2025. It was never in 503B Category 2, where the peptide entries are GHRP-2, GHRP-6 and ipamorelin acetate.
Where the "legal now" story came from
Three substitutions produce the headline. "Withdrawn from Category 2" is read as "cleared by FDA," when the withdrawal was the nominators' and FDA's safety text is still posted. "A committee majority voted yes" is read as "FDA voted yes," when the tally is a press figure, the committee is advisory, and FDA staff recommended the opposite. "FDA is considering the bulks list" is read as "it is on the bulks list," when the list is a codified regulation that has not been amended. Each substitution moves BPC-157 one step closer to a pharmacy shelf than any FDA document places it.
Status table as of September 21, 2026
| Question | Answer | Source |
|---|---|---|
| Controlled substance? | No | 21 U.S.C. 802(41) |
| FDA-approved product? | No | Drugs@FDA; 503A nomination record; WADA S0 wording |
| US trials? | One Phase 1, not yet recruiting (University of Arkansas); no sponsor-run pivotal program | ClinicalTrials.gov, September 21, 2026 |
| 503A category? | None; Category 2 from September 29, 2023 until nominations withdrawn, page dated April 22, 2026; not in Category 1 (May 14, 2026 list) | FDA Category 2 page; FDA Category 1 document |
| On the 503A bulks list? | No | 21 CFR 216.23 |
| FDA's July 2026 position? | Proposed that neither free base nor acetate be added | PCAC briefing document |
| PCAC vote? | 8-6-1 in favor, as reported by press; no FDA tally; non-binding | TIME; OpenLoop Health; FDA meeting page |
| Rulemaking since? | None found | fda.gov; federalregister.gov |
| 503B category? | None | FDA 503B list, March 21, 2025 |
| WADA 2026? | S0, prohibited at all times, Specified Substance | WADA 2026 Prohibited List |
Nothing in this article changes what a research vial is: a chemical of stated identity and purity, supplied for laboratory work, with a certificate that says what is in it and a second laboratory that checked, and the line this site draws around it is in what "research use only" actually means.
Sources
- BPC-157, PubChem CID 9941957, National Library of Medicine
- ClinicalTrials.gov search for BPC-157, National Library of Medicine, queried September 21, 2026
- Certain bulk drug substances for use in compounding that may present significant safety risks, FDA, content current as of April 22, 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (PDF), FDA, updated May 14, 2026
- Bulk drug substances used in compounding under section 503A, FDA, content current as of May 14, 2026
- 503B bulk drug substance categories (PDF), FDA, updated March 21, 2025
- 21 CFR 216.23, govinfo, 2024 edition
- PCAC Briefing Document, Introduction (PDF), FDA, July 2026
- Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026, FDA, content current as of August 6, 2026
- FDA committee votes on peptides, TIME, July 23, 2026
- The 2026 Prohibited List, WADA, valid January 1, 2026
- 21 U.S.C. 802, Definitions, U.S. Code, current
For laboratory research use only. Not a drug, not a supplement, and nothing here is a claim about what any of this material does in a person or an animal.